## Supplemental material

# Hemojuvelin mediated hepcidin induction requires both bone morphogenetic protein type I receptors ALK2 and ALK3

Deniz Y. Dogan<sup>1,2</sup>, Eugen I. Urzica<sup>3</sup>, Isabelle Hornung<sup>1</sup>, Philipp Kastl<sup>4</sup>, David Oguama<sup>3</sup>, Franca M. Fette<sup>3</sup>, Lien H. Nguyen<sup>3</sup>, Frank Rosenbauer<sup>5</sup>, Kai Zacharowski<sup>1</sup>, Ursula Klingmüller<sup>4</sup>, Elise Gradhand<sup>6</sup>, Andreas Von Knethen<sup>1</sup>, Rüdiger Popp<sup>7</sup>, Ingrid Fleming<sup>7,8</sup>, Lisa Schrader<sup>1,3,#</sup> and Andrea U. Steinbicker<sup>1,3,#</sup>

<sup>1</sup>Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Goethe University, Frankfurt, Germany

<sup>2</sup>Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin, Charité -Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

<sup>3</sup>Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Muenster, University of Muenster, Muenster, Germany

<sup>4</sup>Division Systems Biology of Signal Transduction, German Cancer Research Center (DKFZ), Heidelberg, Germany.

<sup>5</sup>Institute of Molecular Tumor Biology, University Hospital Muenster, University of Muenster, Muenster, Germany

<sup>6</sup>Senckenberg Institute for Pathology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany <sup>7</sup>Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, 60590 Frankfurt, Germany

<sup>8</sup>German Centre for Cardiovascular Research (DZHK) Partner Site Rhein Main, 80336 Munich, Germany

# contributed equally



**AAV2/8-ALB-mHFE2-MycDDK vector map.** The AAV vector map was provided by Vector Biolabs and was created with SnapGene. *Hjv-MycDDK* is expressed under the control of a liver-specific promotor (ALB). MycDDK-tag is located at the C-terminus of HJV.



**AAV2/8-ALB-mHFE2-MycDDK induces liver specific HJV expression. (A)** HJV protein level in AAV-HJV injected hepatocyte-specific *Alk2*-deficient mice and their control littermates and **(B)** hepatocyte-specific *Alk3*-deficient mice and their control littermates were determined to validate the hepatic overexpression of HJV. GAPDH was used as internal control. Relative HJV protein expression was determined by densitometric analysis of immunoblots (n: *Alk2<sup>fl/fl</sup>* PBS = 3, *Alk2<sup>fl/fl</sup>*, *Alb-Cre* PBS= 3, *Alk2<sup>fl/fl</sup>*, *AAV-HJV* = 4, *Alk2<sup>fl/fl</sup>*, *Alb-Cre* AAV-HJV= 4, *Alk3<sup>fl/fl</sup>* PBS= *3*, *Alk3<sup>fl/fl</sup>*, *Alb-Cre* PBS=3, *Alk3<sup>fl/fl</sup>*, *AAV-HJV* = 3, *Alk3<sup>fl/fl</sup>*, *Alb-Cre* AAV-HJV=3). **(C)** HJV protein level were detected in sera of Cre- and Cre+ mice overexpressing HJV. A liver sample of an AAV-HJV injected animal and a liver sample of *Hjv* KO mouse was used as control. **(D)** Splenic and hepatic HJV protein level in AAV-HJV injected mice were determined by immunoblotting to validate a liver specific HJV overexpression. GAPDH was used as internal control.



*HJV* mRNA levels correlate with *Hamp* mRNA levels in control mice. (A) *Hjv* mRNA expression positively correlated with *Hamp* mRNA levels in control mice (R=0.6579). Every mouse represents one data point (n=23). (B) In contrast, there was no correlation between *Hjv* mRNA expression and *Hamp* mRNA in *Alk2<sup>fl/fl</sup>; Alb-Cre* and *Alk3<sup>fl/fl</sup>; Alb-Cre* mice (R=-0.4377). Every mouse represents one data point (n=21). (C) Phosphorylated SMAD1/5/8 levels were determined by immunoblotting and showed that after HJV overexpression there was little signaling activity in *Alk2<sup>fl/fl</sup>; Alb-Cre* mice, but no activity in *Alk3<sup>fl/fl</sup>; Alb-Cre* mice (n=3 per group).



HJV overexpression effects Ferritin, Heavy Chain, expression in *Alk3*<sup>*fl/fl*</sup>;*Alb-Cre* mice. (A) Ferritin, Heavy chain (FTH), protein expression in *Alk2*<sup>*fl/fl*</sup>;*Alb-Cre* mice was determined via immunoblotting. GAPDH was used as internal control (n =3 per group). (B) Relative FTH protein expression was determined by densitometric analysis of immunoblots. HJV overexpression had no effects on FTH protein levels in *Alk2*<sup>*fl/fl*</sup>;*Alb-Cre* mice. (C) Ferritin, Heavy chain (FTH), protein expression in *Alk3*<sup>*fl/fl*</sup>;*Alb-Cre* mice was determined via immunoblotting. Beta-Actin was used as internal control (n =3 per group). (D) Relative FTH protein expression was determined by densitometric analysis of immunoblots. In *Alk3*<sup>*fl/fl*</sup>;*Alb-Cre* mice, HJV overexpression further decreased FTH protein levels.

m <i>Hamp</i>	F : 5'-AAGCAGGGCAGACATTGCGAT-3'
	R : 5'-CAGGATGTGGCTCTAGGCTATGT-3'
m <i>HJV</i>	F : 5'-ATGGGCCAGTCCCCTAGTC-3'
	R : 5'-GACGAGACATACTCGGCATTG-3'
m <i>18</i> S	F: 5'-CGGCTACCACTCCAAGGAA-3'
	R: 5'-GCTGGAATTACCGCGGCT-3'
mld1	F: 5'-TCTGTCGGAGCAAAGCGTGGCC-3'
	R: 5'-CCGGTGGTCCCGACTTCAGACT-3'
mErfe	F: 5'-ATGGGGCTGGAGAACAGC-3'
	R: 5'-TGGCATTGTCCAAGAAGACA-3'
mBMP-6	F: 5'-ATGGCAGGACTGGATCATTGC-3'
	R: 5'-CCATCACAGTAGTTGGCAGCG-3'
Alk2 (Taqman)	Mm00431646_m1 Acvr1 FAM

Supplemental Table 1. Primers used for quantitative Reverse-Transcriptase PCR

Alk3 (Taqman)	Bmpr1a- Mm00477650_m1 Bmpr1a
18S (Taqman)	RN 18S-Mm03928990_g1